Announced Date: 2021-07-12 (July 12, 2021) Asset Name: Orelabrutinib Licensor (Seller): InnoCare Pharma (China) Licensee (Buyer): … [China BD 2021] Allist Pharma and ArriVent enters a 150 million USD License on EGFR TKI Orelabrutinib for the potential treatment of multiple sclerosis (MS)Read more
China License Out
[China BD 2020] I-Mab and Abbvie enters a License on anti-CD47 monoclonal antibody Lemzoparlimab (TJC4)
Announced Date: 2020-09-04 (September 04, 2020) Asset Name: Lemzoparlimab (TJC4) Licensor (Seller): I-MAB Biopharma (China) Licensee (Buyer): … [China BD 2020] I-Mab and Abbvie enters a License on anti-CD47 monoclonal antibody Lemzoparlimab (TJC4)Read more
[China BD 2020] Jacobio and Abbvie enters a License on SHP2 inhibitors portfolio
Announced Date: 2020-06-01 (June 1, 2020) Asset Name: JAB-3068 and JAB-3312 Licensor (Seller): Jacobio Pharmaceuticals (China) … [China BD 2020] Jacobio and Abbvie enters a License on SHP2 inhibitors portfolioRead more